Testosterone Cypionate Injectable Recalled for Lack of Sterility Assurance
Vita Pharmacy, LLC dba Talon Compounding Pharmacy is recalling Testosterone Cypionate 25mg/mL Injectable due to lack of assurance of sterility. The product was distributed in the United States including Washington, D.C. and Puerto Rico.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II recall of an injectable pharmaceutical product. Lack of sterility assurance in injectable medication represents a significant risk of harm because contaminated injectables can cause serious infection. Although no illnesses are reported in the source text, sterile injectable products are high-risk, and the agency's Class II classification for this type of defect warrants a Severe rating per the rubric.
Plain-English summary
Vita Pharmacy, LLC dba Talon Compounding Pharmacy is recalling Testosterone Cypionate 25mg/mL Injectable in Ethyl Oleate (prescription-only) due to lack of assurance of sterility. The recalled product was distributed across the United States, including Washington, D.C. and Puerto Rico.
The affected lots are: T0508192021:06 (BUD 02/15/2022); T0507022021:91 (BUD 12/29/2021); T0507192021:13 (BUD 01/15/2022); T0504262021:71 (BUD 10/23/2021); and T0509172021:03 (BUD 03/16/2022). The product was supplied as 16 vials per unit by Talon Compounding Pharmacy, located at 2950 Thousand Oaks Drive Ste 25, San Antonio, Texas 78247.
Consumers who have received this product should consult their healthcare provider or pharmacist regarding the recall and any further instructions. The FDA classifies this as a Class II recall.
The recalled product
- Product
- TESTOSTERONE CYPIONATE 25MG/ML INJ #1 IN ETHYL OLEATE INJECTABLE, Rx only, Talon Compounding Pharmacy, 2950 Thousand Oaks Drive Ste 25, San Antonio, Texas 78247
- Manufacturer
- Vita Pharmacy, LLC dba Talon Compounding Pharmacy
- Hazard
- sterility-failure
- injection-contamination
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot: T0508192021:06 BUD: 02/15/2022
- T0507022021:91 BUD: 12/29/2021
- T0507192021:13 BUD: 01/15/2022
- T0504262021:71 BUD: 10/23/2021
- T0509172021:03 BUD: 03/16/2022
Distribution
Distribution scope not specified by the agency.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27